Topiramate Capsule
Product Images NDC 51407-893

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 51407-893). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

51407-893-60ol (Topiramate 15 mg)

51407-893-60ol (Topiramate 15 mg)
Each capsule contains topiramate, USP equivalent to 15 mg. The capsules are white to off-white in color and contain coated pellets. The medication should be dispensed in a tight container and protected from moisture. The capsules are marked as "15 mg" and "TWi T210". It is important to keep this medication out of the reach of children and store it at 20° - 25°C. Pharmacies should dispense the Medication Guide to each patient. For further details, refer to the Prescribing Information available at the provided link.*
FDA Label Image

51407-894-60ol (Topiramate 25 mg)

51407-894-60ol (Topiramate 25 mg)
This text describes Topiramate capsules, USP, with NDC 51407-894-60. Each capsule contains topiramate equivalent to 25 mg. The medication guide should be dispensed to each patient. The capsules are white to off-white and spherical-shaped. It is important to store the medication in a tight container, protect from moisture, and keep it out of reach of children. The capsules are marked as "25 mg" on the body and "TWi T211" on the cap. Refer to the accompanying Prescribing Information for dosage details. Store between 20°-25°C (68°-77°F) with excursions permitted to 15°-30°C (59°-86°F) as per USP guidelines. Marketed by GSMS, Incorporated based in Camarillo, CA, 93012, USA.*
FDA Label Image

Figure1 (Figure 1)

Figure1 (Figure 1)
This is a chart displaying cumulative rates for the time to the first seizure between two groups of participants - one group taking Topamax 50 mg/day (N=234) and the other group taking Topamax 400 mg/day (N=236). The graph indicates that the higher dosage of Topamax (400 mg/day) resulted in a significantly lower rate of seizures compared to the lower dosage group. The p-value for this difference is 0.0002, showing a statistically significant result. The x-axis represents time in days and the y-axis shows the cumulative rates for seizures.*
FDA Label Image

Figure2 (Figure 2)

Figure2 (Figure 2)
This text provides information about the change from baseline in the average monthly migraine period rate during a double-blind phase for different dosages of Topamax compared to a placebo. The data shows the numbers of subjects in each group for the study. Note the significance level indicated by "*" and "**".*
FDA Label Image

Logo (Logo 2)

Logo (Logo 2)
FDA Label Image

Structure (Structure)

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.